Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18693402 | 0.88 | PIK3CD (0.39) | PIK3CDALDH1A1 | |
| SCHEMBL21372244 | 0.78 | JAK2 (0.40) | JAK2JAK1TYK2JAK3PIK3CD | |
| SCHEMBL4826728 | 0.77 | — | — | |
| SCHEMBL195898 | 0.75 | — | — | |
| SCHEMBL24393346 | 0.73 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL2625903 | 0.73 | PIK3CD (0.43) | PIK3CDALDH1A1 | |
| SCHEMBL3957140 | 0.72 | NPC1 (0.33) | JAK2JAK1TYK2JAK3PIK3CD | |
| SCHEMBL24814059 | 0.72 | — | — | |
| SCHEMBL24393396 | 0.72 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL24815132 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207186-B2 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1896421-B1 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-1896422-B1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MERCK SHARP & DOHME LLC | 2009-08-06 | — | — | US | disclosed |
| US-7550478-B2 | Tyrosine kinase inhibitors | MERCK & CO. INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1896422-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896421-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | Merck & Co., Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002254-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002258-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293358-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME LLC | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293358-A1 | Tyrosine kinase inhibitors | ABL1, ERBB2, RET | JAK2 12/4885JAK1 44/4885TYK2 312/4885 |
| US-20090197908-A1 | Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met | MET, RET, ERBB2 | JAK2 18/4885JAK1 130/4885TYK2 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.